CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 

Revolution Medicines Inc 's Tangible Leverage Ratio

RVMD's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




RVMD Tangible Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity Change 7.86 % -30.34 % -26.34 % 32.31 % 31.26 %
Y / Y Total Liabilities Change 49.31 % 50.45 % 47.95 % 922.73 % 1149.48 %
Tangible Leverage Ratio MRQ 0.24 0.32 0.28 0.26 0.17
Overall Ranking # # # # #
Seq. Tangible Equity Change 43.03 % -10.88 % -9.72 % -6.28 % -7.63 %
Seq. Total Liabilities Change 7.86 % 1.65 % -2.69 % 39.94 % 8.68 %



Tangible Leverage Ratio third quarter 2022 Comment
In Spite of the net new borrowings of 7.86% Revolution Medicines Inc managed to improve Tangible Leverage Ratio in the third quarter 2022 to 0.24, above company's average Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved lowest Tangible Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Tangible Leverage Ratio?
What is RVMD Market Share?
Tangible Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Tangible Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Revolution Medicines Inc 's Tangible Equity $ 608 Millions Visit RVMD's Balance sheet
Revolution Medicines Inc 's Total Liabilities $ 144 Millions Visit RVMD's Balance sheet
Source of RVMD's Sales Visit RVMD's Sales by Geography


Cumulative Revolution Medicines Inc 's Tangible Leverage Ratio

RVMD's Tangible Leverage Ratio for the trailling 12 Months

RVMD Tangible Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity TTM Growth 7.86 % -30.34 % -26.34 % 32.31 % 31.26 %
Y / Y Total Liabilities TTM Growth 49.31 % 50.45 % 47.95 % 922.73 % 1149.48 %
Tangible Leverage Ratio TTM 0.27 0.25 0.21 0.17 0.13
Total Ranking TTM # 389 # 553 # 269 # 452 # 354
Seq. Tangible Equity TTM Growth 43.03 % -10.88 % -9.72 % -6.28 % -7.63 %
Seq. Total Liabilities TTM Growth 7.86 % 1.65 % -2.69 % 39.94 % 8.68 %


TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Due to net new borrowings of 7.86%, Tangible Leverage Ratio improved to 0.27, above Revolution Medicines Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 54 other companies have achieved lower Tangible Leverage Ratio than Revolution Medicines Inc . While total ranking remained unchanged compare to previous quarter at no. 389.

Explain Tangible Leverage Ratio?
What is RVMD Market Share?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 55
Healthcare Sector # 244
Within the Market # 389


TTM Tangible Leverage Ratio Statistics
High Average Low
0.23 0.18 0.15
(Sep 30 2022)   (Sep 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Tangible Equity
Poseida Therapeutics Inc   0.64 $ 134.387  Millions$ 210.765  Millions
Natural Health Trends Corp   0.63 $ 32.686  Millions$ 51.909  Millions
Candel Therapeutics Inc   0.62 $ 32.428  Millions$ 52.127  Millions
Nanovibronix Inc  0.61 $ 1.909  Millions$ 3.154  Millions
Recursion Pharmaceuticals Inc   0.58 $ 223.499  Millions$ 385.776  Millions
Regenxbio Inc   0.57 $ 319.969  Millions$ 563.824  Millions
Finch Therapeutics Group Inc   0.56 $ 67.102  Millions$ 120.866  Millions
Century Therapeutics inc   0.55 $ 181.546  Millions$ 330.205  Millions
Bluebird Bio Inc   0.54 $ 83.028  Millions$ 153.211  Millions
Myomo Inc   0.53 $ 4.114  Millions$ 7.822  Millions
Denali Therapeutics Inc   0.51 $ 416.303  Millions$ 811.303  Millions
Alpha Teknova Inc   0.51 $ 48.276  Millions$ 94.153  Millions
Kodiak Sciences Inc   0.51 $ 244.459  Millions$ 479.529  Millions
Edwards Lifesciences Corporation  0.51 $ 2,420.400  Millions$ 4,792.600  Millions
Gritstone Bio Inc   0.50 $ 68.395  Millions$ 136.847  Millions
Vaxart Inc   0.49 $ 53.002  Millions$ 108.188  Millions
Berkeley Lights Inc   0.48 $ 76.701  Millions$ 158.183  Millions
Voyager Therapeutics Inc   0.48 $ 38.636  Millions$ 79.823  Millions
Bio rad Laboratories Inc   0.46 $ 3,570.814  Millions$ 7,728.940  Millions
Immucell Corp  0.45 $ 14.419  Millions$ 31.825  Millions
C4 Therapeutics Inc   0.45 $ 143.260  Millions$ 318.179  Millions
Inogen Inc   0.45 $ 118.742  Millions$ 264.468  Millions
Moderna Inc   0.45 $ 8,064.000  Millions$ 17,992.000  Millions
Arcellx Inc   0.43 $ 101.043  Millions$ 236.284  Millions
Inmune Bio Inc   0.43 $ 20.094  Millions$ 47.192  Millions
Cue Health Inc   0.41 $ 235.076  Millions$ 573.916  Millions
Vericel Corporation  0.39 $ 70.180  Millions$ 177.837  Millions
Neurocrine Biosciences Inc   0.39 $ 598.800  Millions$ 1,544.600  Millions
Surface Oncology Inc   0.39 $ 43.454  Millions$ 112.819  Millions
Vicarious Surgical Inc   0.38 $ 41.723  Millions$ 108.952  Millions

Date modified: 2022-11-08T18:12:02+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RSAP's Profile

Stock Price

RSAP's Financials

Business Description

Fundamentals

Charts & Quotes

RSAP's News

Suppliers

RSAP's Competitors

Customers & Markets

Economic Indicators

RSAP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071